Completed PHASE1 INTERVENTIONAL 1-arm NCT04702503

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Adults With Stage I, II, or III Mycosis Fungoides (Cutaneous T-Cell Lymphoma, CTCL)

Sponsor: Moleculin Biotech, Inc.

Conditions Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions WP1220

Updated 3 times since 2021 Last updated: Jan 8, 2021 Started: Mar 8, 2019 Primary completion: Nov 15, 2019 Completion: Nov 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cutaneous T-Cell Lymphoma/Mycosis Fungoides and is currently completed. Moleculin Biotech, Inc. leads this study, which shows 3 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2021 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Moleculin Biotech, Inc.

Data source: Moleculin Biotech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gdansk, Poland